NCI CTEP-Approved Trials for the Month of February

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Phase II

GOG-0283: A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression. Gynecologic Oncology Group; Hyman, David Michael. (212) 639-2000

Phase III

E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765) Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL). Eastern Cooperative Oncology Group; Shanafelt, Tait D. 507-284-2358

Other Phases

AAML13B7-Q: Prognostic Significance of MMRN1 in Pediatric Acute Myeloid Leukemia (AML). Children’s Oncology Group; Walter, Roland Bruno. (206) 667-3599

AAML13B8-Q: Global Proteomic and Phosphoproteomic Profiling of Normal B Cells Isolated from COG AAML1031 Study Patients in AML Remission. Children’s Oncology Group; Pandey, Akhilesh. (410) 502-6662

ANBL13B9-Q: 3D Nuclear Telomere Organization in Neuroblastoma. Children’s Oncology Group; Mai, Sabine. (204) 787-2135

ANBL13B10-Q: The Role of FGFR4 in Neuroblastoma Pathogenesis. Children’s Oncology Group; Zage, Peter Eric. (832) 824-4615

AREN13B2-Q: Characterization of the Chromosome 11p15 Imprinting Regulation by Epigenetic and Transcriptomic Analyses in Wilms Tumor Patients. Children’s Oncology Group; Michels, Karin B. (617) 732-4895

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Reimagining cancer care for a new generation of patients

The landscape of cancer is shifting beneath our feet, and we must adapt our clinical practice accordingly.

June 06, 2025

Vol.51 No.22

By Hope S. Rugo

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.

June 06, 2025

Vol.51 No.22

By Jacquelyn Cobb

Clinical Trials & Tribulations

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Our Hispanic community is a vibrant and essential part of the American tapestry, contributing richly to the country’s society, culture, and economy. Yet, when it comes to healthcare, this community grapples with significant disparities, especially in cancer care.

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Harmon Eyre, MD, died on May 31 in Salt Lake City. He was 84 years old. From 1993 to 2008, he served as the chief medical and scientific officer (CMSO) of the American Cancer Society.

Melvin J. Silverstein reflects on 25 years of controversy surrounding DCIS and radiation

Silverstein during his surgical oncology fellowship, c. 1972This month on the Cancer History Project Podcast, Melvin J. Silverstein, Medical Director of Hoag Breast Center and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at USC, sat down with Stacy Wentworth, radiation oncologist and medical historian, to reflect on his career—and founding the first free-standing breast center.

June 06, 2025

Vol.51 No.22

NCI CTEP-Approved Trials for the Month of February

YOU MAY BE INTERESTED IN

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Melvin J. Silverstein reflects on 25 years of controversy surrounding DCIS and radiation

Renew today!

Subscriber content

Never miss an issue!

Login

NCI CTEP-Approved Trials for the Month of February

YOU MAY BE INTERESTED IN

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher findsCells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Bridging the gaps in cancer care for Hispanics: Striving for equity and fairness in scientific advancements

Harmon Eyre, former ACS chief medical and scientific officer, dies at 84

Melvin J. Silverstein reflects on 25 years of controversy surrounding DCIS and radiation

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response